Clinical Trial Update: A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the combination of RDEA3170 with febuxostat for gout and asymptomatic hyperuricemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Hyperuricemia

Drugs mentioned

• FEBUXOSTAT (Febuxostat)
• RDEA3170 (RDEA3170)

Snippet

Sponsor: AstraZeneca | Conditions: Gout and Asymptomatic Hyperuricemia | Phase 1, Phase 2 | Status: COMPLETED